CONMED Corp.

Biopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede

Biopharma Acquisitions Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceed

Biopharma financings during the second quarter of 2022 reached $12.5bn. The largest was by Blueprint Medicines Corporation (precision therapies for cancer and blood disorders) through an arrangement

The global market for arthroscopy products and sports medicine implants is projected to remain relatively stagnant compared to other markets, growing from $5.7bn in 2020 to $6.3bn in 2025, a compound